These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33810909)

  • 1. Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.
    Vail W; Faro E; Watnick D; Giftos J; Fox AD
    Drug Alcohol Depend; 2021 May; 222():108529. PubMed ID: 33810909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study.
    Stopka TJ; Rottapel R; Friedmann PD; Pivovarova E; Evans EA
    Addict Sci Clin Pract; 2024 Sep; 19(1):68. PubMed ID: 39267138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
    Cherian T; Lim S; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
    Drug Alcohol Depend; 2024 Jun; 259():111274. PubMed ID: 38643529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories.
    Hoffman KA; Thompson E; Gaeta Gazzola M; Oberleitner LMS; Eller A; Madden LM; Marcus R; Oberleitner DE; Beitel M; Barry DT
    Addict Sci Clin Pract; 2023 Mar; 18(1):16. PubMed ID: 36944998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
    Cheng A; Badolato R; Segoshi A; McDonald R; Malone M; Vasudevan K; Badiei B; Sugarman A; Macdonald R; Mangat J; Giftos J; Lee JD; Tofighi B
    Addict Sci Clin Pract; 2022 Jan; 17(1):4. PubMed ID: 35093164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
    Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
    Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of non-prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration.
    Gryczynski J; Lee JD; Dusek K; McDonald R; Sharma A; Malone M; Monico LB; Cheng A; DeVeaugh-Geiss A; Chilcoat HD
    J Subst Abuse Treat; 2021 Aug; 127():108349. PubMed ID: 34134866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
    Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R
    JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration.
    Monico LB; Gryczynski J; Lee JD; Dusek K; McDonald R; Malone M; Sharma A; Cheng A; DeVeaugh-Geiss A; Chilcoat H
    J Subst Abuse Treat; 2021 Apr; 123():108267. PubMed ID: 33612198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study.
    Krawczyk N; Lim S; Cherian T; Goldfeld KS; Katyal M; Rivera BD; McDonald R; Khan M; Wiewel E; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Kutscher E; Khatri UG; Rosner Z; Vail WL; MacDonald R; Lee JD
    Drug Alcohol Depend; 2024 Aug; 261():111377. PubMed ID: 38924958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder.
    Evans EA; Wilson D; Friedmann PD
    Drug Alcohol Depend; 2022 Feb; 231():109254. PubMed ID: 35063323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "I Kicked the Hard Way. I Got Incarcerated." Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments.
    Maradiaga JA; Nahvi S; Cunningham CO; Sanchez J; Fox AD
    J Subst Abuse Treat; 2016 Mar; 62():49-54. PubMed ID: 26747509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
    Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
    Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19.
    Harrington C; Bailey A; Delorme E; Hano S; Evans EA
    Subst Use Misuse; 2023; 58(2):266-274. PubMed ID: 36510800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.